5 minAt the 2026 Alzheimer’s Association International Conference (AAIC 2026), Biogen officially unveiled the full Phase 2 data from its CELIA study of Diranersen (BIIB080), a Tau-targeting antisense oligonucleotide (ASO) therapy. Following the previously reported topline results, this comprehensive disclosure provides systematic evidence across clinical endpoints, Tau biomarkers, and safety, marking one of the most significant clinical advancements in the Tau therapeutic field in recent years.
Most notably, Biogen announced that it will officially advance Diranersen into Phase 3 confirmatory clinical development. This move signals that after years dominated by the "Aβ (Amyloid-β) monoclonal antibody era," the Alzheimer’s disease (AD) treatment landscape is entering a critical new stage centered on the Tau pathway—the second core pathological mechanism of the disease.
Why Tau Therapy Has Returned to the Industry Spotlight
For over two decades, Alzheimer’s drug development has primarily revolved around Amyloid-β. The approval of agents like Leqembi and Kisunla validated that Aβ clearance can slow disease progression to a degree. However, mounting evidence suggests a more direct and robust correlation between cognitive decline and the abnormal accumulation of Tau protein.
Abnormally phosphorylated Tau forms neurofibrillary tangles (NFTs), which not only impair neuronal function but also propagate along neural networks, acting as a primary driver of sustained disease progression. Consequently, Tau has increasingly been viewed as the most critical therapeutic target after Aβ.
However, Tau drug development has been fraught with challenges. Previous failures—including Tau vaccines, antibodies, and small-molecule inhibitors—led the industry to believe that Tau-based mechanisms were still far from clinical validation. The Diranersen data, however, provide the first Phase 2 evidence simultaneously demonstrating significant Tau reduction, improvement in PET imaging, and cognitive benefit, reigniting confidence in the Tau hypothesis.
The CELIA Study: 416 Patients, 18 Months, and Tau Validation
The CELIA study was a global, multicenter, randomized, double-blind, placebo-controlled Phase 2 dose-finding trial involving 416 patients with early Alzheimer’s disease (encompassing both Mild Cognitive Impairment and mild AD dementia). The cohort had a mean age of 68 years, with 51% female representation. About 69% of participants carried the ApoE4 risk gene, ensuring a representative patient demographic.
Participants, who were naive to anti-Aβ therapy, were randomized into three dosage regimens:
-
60 mg every 6 months;
-
115 mg every 6 months;
-
115 mg every 3 months. The primary observation period was 18 months (76 weeks).
Clinical Efficacy: Consistent Slowing of Disease Progression
The most compelling finding from the data is that Diranersen demonstrated a slowing of disease progression across multiple predefined clinical endpoints. The 60 mg every-6-month regimen showed the most robust performance:
Compared to placebo at 18 months, this dose resulted in:
-
26% slower decline in CDR-SB (0.54 points);
-
42% slower decline in ADAS-Cog13 cognitive score;
-
50% slower decline in MMSE;
-
30% slower decline in modified iADRS;
-
23% slower decline in ADCOMS.
While the two 115 mg dose cohorts showed consistent therapeutic trends, the study did not achieve its predefined primary endpoint of dose-response on CDR-SB. However, the observation that the lower dose (60 mg) provided optimal integrated clinical benefit suggests that Tau intervention may have a specific "therapeutic window" rather than a simple dose-dependent effect.
Biomarker Results: A 50%–65% Reduction in Tau
Of paramount interest to the scientific community was the impact on biomarkers. Across all dose groups:
-
Total Tau protein in cerebrospinal fluid (CSF) decreased by an average of 50%–65%;
-
Tau PET imaging showed a marked decrease in Tau deposition across multiple brain regions.
Biogen noted that this is the world’s first Tau-targeted therapy in a Phase 2 study to demonstrate significant improvement in both CSF Tau and Tau PET. This establishes a relatively complete evidentiary chain linking "mechanism of action—biomarkers—clinical benefit."
Diranersen: Inhibiting Tau at the Source
Unlike traditional Tau antibodies that target extracellular Tau proteins for clearance, Diranersen, as an ASO, directly targets MAPT mRNA to inhibit Tau protein expression at the RNA level. By intervening before protein synthesis, Diranersen reduces:
-
Intracellular Tau;
-
Extracellular Tau;
-
All Tau isoforms.
Safety Profile: No ARIA Risk Observed
Diranersen was generally well-tolerated. Most adverse events were mild to moderate, with the most common being lumbar puncture-related pain, post-lumbar puncture syndrome, and transient confusion (typically resolving within one week). Notably, because Diranersen does not target Aβ, it theoretically avoids the risk of Amyloid-Related Imaging Abnormalities (ARIA). The study confirmed that no mechanism-related ARIA issues occurred. Over 90% of patients chose to continue into the long-term extension (LTE) study, reflecting high patient tolerance and willingness to continue treatment.
Moving Toward a "Dual-Target Era"
The CELIA study data signal that Tau has become the most promising core target following Aβ. While the study had limitations regarding its primary dose-response endpoint, the consistency of the clinical, biomarker, and safety data provides a strong "Proof of Concept."
If Phase 3 studies replicate these Phase 2 results, Diranersen could become the world’s first approved Tau-targeting ASO therapy, potentially propelling Alzheimer’s treatment from a single-target (Aβ) approach to a new paradigm of Aβ + Tau combination therapy. For the neurodegenerative disease pipeline, this is not only a revitalization of the Tau space but also further evidence of the immense potential for RNA therapeutics in treating central nervous system disorders. The future of Alzheimer’s innovation likely lies in multi-mechanism combination strategies involving Tau, neuroinflammation, and neuroprotection.
